JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

Search

PerkinElmer Inc

Suletud

SektorTervishoid

0

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad

By Trading Economics

Sissetulek

13M

55M

Müük

56M

720M

P/E

Sektori keskmine

41.322

38.156

Aktsiakasum

1.18

Dividenditootlus

0.14

Kasumimarginaal

7.569

Töötajad

11,000

EBITDA

-82M

91M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+21.97% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.14%

2.50%

Järgmine dividendimakse kuupäev

8. aug 2025

Järgmine aktsia dividendi kuupäev (ex-date)

17. okt 2025

Turustatistika

By TradingEconomics

Turukapital

509M

11B

Eelmine avamishind

0

Eelmine sulgemishind

0

Uudiste sentiment

By Acuity

38%

62%

119 / 375 Pingereas Healthcare

PerkinElmer Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. juuli 2025, 23:57 UTC

Omandamised, ülevõtmised, äriostud

EQT: To Spend Y407.82B for Tender Offer

29. juuli 2025, 23:56 UTC

Omandamised, ülevõtmised, äriostud

EQT: Tender Offer Price Is Y5,700 a Share

29. juuli 2025, 23:54 UTC

Omandamised, ülevõtmised, äriostud

EQT To Start Tender Offer for Fujitec

29. juuli 2025, 23:50 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29. juuli 2025, 23:36 UTC

Market Talk

Gold Steady Ahead of FOMC Decision -- Market Talk

29. juuli 2025, 22:57 UTC

Market Talk

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29. juuli 2025, 22:50 UTC

Market Talk

Mondelez Warns of Price Increases in North America -- Market Talk

29. juuli 2025, 22:44 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29. juuli 2025, 22:41 UTC

Omandamised, ülevõtmised, äriostud

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29. juuli 2025, 22:41 UTC

Omandamised, ülevõtmised, äriostud

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29. juuli 2025, 22:35 UTC

Tulu

IGO Maintains Nova Life of Mine Production Guidance

29. juuli 2025, 22:35 UTC

Tulu

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29. juuli 2025, 22:35 UTC

Tulu

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29. juuli 2025, 22:34 UTC

Tulu

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29. juuli 2025, 22:34 UTC

Tulu

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29. juuli 2025, 22:34 UTC

Market Talk
Tulu

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29. juuli 2025, 22:33 UTC

Tulu

IGO Had A$279.7 Million of Cash at End-June

29. juuli 2025, 22:33 UTC

Tulu

IGO 4Q Underlying Free Cash A$2.4 Million

29. juuli 2025, 22:33 UTC

Tulu

IGO FY Sales Revenue A$512.5 Million

29. juuli 2025, 22:33 UTC

Tulu

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29. juuli 2025, 22:32 UTC

Tulu

IGO FY Nickel Production 17,173 Tons

29. juuli 2025, 22:32 UTC

Tulu

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29. juuli 2025, 22:32 UTC

Tulu

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29. juuli 2025, 22:31 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

29. juuli 2025, 22:31 UTC

Market Talk
Tulu

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29. juuli 2025, 22:31 UTC

Tulu

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29. juuli 2025, 22:31 UTC

Tulu

IGO FY Spodumene Production 1.48 Million Tons

29. juuli 2025, 22:30 UTC

Tulu

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29. juuli 2025, 22:30 UTC

Tulu

IGO 4Q Underlying Ebitda A$62 Million

29. juuli 2025, 22:22 UTC

Tulu

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Võrdlus sarnastega

Hinnamuutus

PerkinElmer Inc Prognoos

Hinnasiht

By TipRanks

21.97% tõus

12 kuu keskmine prognoos

Keskmine 115.92 USD  21.97%

Kõrge 135 USD

Madal 100 USD

Põhineb 13 Wall Streeti analüütiku instrumendi PerkinElmer Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

13 ratings

9

Osta

4

Hoia

0

Müü

Sentiment

By Acuity

119 / 375 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.